

Accepted Manuscript

Impact of fluoroquinolone prophylaxis during neutropenia on bloodstream infection: Data from a surveillance program in 8,755 patients receiving high-dose chemotherapy for haematologic malignancies between 2009 and 2014

Winfried V. Kern , Susanne Weber , Markus Dettenkofer , Klaus Kaier , Hartmut Bertz , Michael Behnke , Maja Weisser , Tim Götting , Andreas F. Widmer , Christian Theilacker , the Hospital Infection Surveillance System for Patients with Haematologic/Oncologic Malignancies Study Group (ONKO-KISS)



PII: S0163-4453(18)30156-7
DOI: [10.1016/j.jinf.2018.05.004](https://doi.org/10.1016/j.jinf.2018.05.004)
Reference: YJINF 4103

To appear in: *Journal of Infection*

Received date: 27 December 2017
Revised date: 5 May 2018
Accepted date: 19 May 2018

Please cite this article as: Winfried V. Kern , Susanne Weber , Markus Dettenkofer , Klaus Kaier , Hartmut Bertz , Michael Behnke , Maja Weisser , Tim Götting , Andreas F. Widmer , Christian Theilacker , the Hospital Infection Surveillance System for Patients with Haematologic/Oncologic Malignancies Study Group (ONKO-KISS), Impact of fluoroquinolone prophylaxis during neutropenia on bloodstream infection: Data from a surveillance program in 8,755 patients receiving high-dose chemotherapy for haematologic malignancies between 2009 and 2014, *Journal of Infection* (2018), doi: [10.1016/j.jinf.2018.05.004](https://doi.org/10.1016/j.jinf.2018.05.004)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Impact of fluoroquinolone prophylaxis during neutropenia on bloodstream infection: Data from a surveillance program in 8,755 patients receiving high-dose chemotherapy for haematologic malignancies between 2009 and 2014

Winfried V. Kern¹⁺, Susanne Weber², Markus Dettenkofer^{3*}, Klaus Kaier², Hartmut Bertz⁴, Michael Behnke⁵, Maja Weisser⁶ Tim Götting³, Andreas F. Widmer⁶ and Christian Theilacker^{6,1*}, and the Hospital Infection Surveillance System for Patients with Haematologic/Oncologic Malignancies Study Group (ONKO-KISS)

¹ *Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, and Faculty of Medicine, Albert-Ludwigs-University, Freiburg, Germany*

² *Institute for Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Germany*

³ *Department of Environmental Health Sciences and Hospital Infection Control, University Hospital and Medical Center, and Faculty of Medicine, Albert-Ludwigs-University, Freiburg, Germany*

⁴ *Division of Hematology, Oncology, and Stem Cell Transplantation, Department of Medicine I, University Hospital and Medical Center, Albert-Ludwigs-University Faculty of Medicine, Freiburg, Germany*

⁵ *Institute for Hygiene and Environmental Medicine, Charité University Medical Center, Berlin, Germany*

⁶ *Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland*

*Present addresses:

Markus Dettenkofer, Gesundheitsverbund Landkreis Konstanz, Hausherrenstraße 12, 78315 Radolfzell, Germany

Christian Theilacker, Pfizer Vaccines, Medical and Scientific Affairs, 23-25 Avenue du Dr. Lannelongue, F-75668 Paris, Cedex 14, France

Running title: Impact of fluoroquinolone prophylaxis in patients with haematologic malignancies

Download English Version:

<https://daneshyari.com/en/article/8740375>

Download Persian Version:

<https://daneshyari.com/article/8740375>

[Daneshyari.com](https://daneshyari.com)